AI-powered chemistry startup Excelsior Sciences raises $95 million to…

Team S · 2025-12-31T08:52:58.000Z

Excelsior Sciences, a New York-based life sciences startup pioneering AI-integrated chemistry for small-molecule discovery and production, has raised $95 million in a Series A funding round to scale its automated smart bloccs platform, expand partnerships and accelerate drug discovery and manufacturing innovation. The financing combines traditional venture capital with public support to help reshape how small molecules are designed, synthesised and tested in a closed-loop workflow that feeds AI with data faster than traditional methods. The round was co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, with additional participation from Cornucopian Capital, Illinois Ventures, Eli Lilly and Company, Massachusetts Institute of Technology (MIT) and a $25 million grant from New York’s Empire State Development. The capital will help fuel internal pipeline development, commercial partnerships across therapeutics and materials science, and build out Excelsior’s integrated discovery/manufacturing infrastructure at its New York facilities. Founded by Michael Foley, PhD, Jana Jensen, PhD, MBA, Marty Burke, MD, PhD, and Bartosz Grzybowski, PhD, the company’s smart bloccs technology uses automated, AI-friendly chemical building blocks to enable iterative synthesis and data generation, bridging the gap between AI design and real-world molecule production. This approach supports drug discovery and manufacturing reshoring efforts and aims to dramatically accelerate timelines from concept to candidate. #AI #biotech #drugdiscovery #smallmolecules #funding #healthtech #automatedchemistry #ExcelsiorSciences

Member Login Get Access

AI-powered chemistry startup Excelsior Sciences raises $95 million to… | Newnex